UY27133A1 - 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides - Google Patents

11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides

Info

Publication number
UY27133A1
UY27133A1 UY27133A UY27133A UY27133A1 UY 27133 A1 UY27133 A1 UY 27133A1 UY 27133 A UY27133 A UY 27133A UY 27133 A UY27133 A UY 27133A UY 27133 A1 UY27133 A1 UY 27133A1
Authority
UY
Uruguay
Prior art keywords
halogenesteroids
obtaining
pharmaceutical preparations
preparations containing
11beta
Prior art date
Application number
UY27133A
Other languages
English (en)
Inventor
Hermann Kunzer
Rolf Bohlmann
Reinhard Nubbemeyer
Dieter Zopf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27133A1 publication Critical patent/UY27133A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a los 11B-halogenesteroides de fórmula general 1, donde R11 es halógeno, X-Y-Z es un grupo con una de las dos estructuras CH=C-C o CH2-C=C y los otros radicales tienen el significado indicado en las reivindicaciones, además a la obtención y al uso de estos compuestos para preparar medicamentos, asi como preparados farmacéuticos que contienen 11B-halogenesteroides.
UY27133A 2001-01-24 2002-01-24 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides UY27133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10104327A DE10104327A1 (de) 2001-01-24 2001-01-24 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
UY27133A1 true UY27133A1 (es) 2002-07-31

Family

ID=7672351

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27133A UY27133A1 (es) 2001-01-24 2002-01-24 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides

Country Status (35)

Country Link
US (1) US7361645B2 (es)
EP (1) EP1353938B1 (es)
JP (1) JP4339591B2 (es)
KR (1) KR100728088B1 (es)
CN (1) CN1234721C (es)
AR (1) AR053299A1 (es)
AT (1) ATE386045T1 (es)
AU (1) AU2002238516B2 (es)
BG (1) BG66133B1 (es)
BR (1) BR0206653A (es)
CA (1) CA2434187C (es)
CY (1) CY1110377T1 (es)
CZ (1) CZ303553B6 (es)
DE (2) DE10104327A1 (es)
DK (1) DK1353938T3 (es)
EA (1) EA006674B1 (es)
EE (1) EE05274B1 (es)
ES (1) ES2300431T3 (es)
HK (1) HK1064678A1 (es)
HR (1) HRP20030661B1 (es)
HU (1) HUP0303020A3 (es)
IL (2) IL156807A0 (es)
MX (1) MXPA03006578A (es)
NO (1) NO325754B1 (es)
NZ (1) NZ527041A (es)
PE (1) PE20020848A1 (es)
PL (1) PL207582B1 (es)
PT (1) PT1353938E (es)
RS (1) RS50740B (es)
SK (1) SK287444B6 (es)
TW (1) TWI333494B (es)
UA (1) UA75907C2 (es)
UY (1) UY27133A1 (es)
WO (1) WO2002059139A1 (es)
ZA (1) ZA200306537B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
DE10233723A1 (de) 2002-07-24 2004-02-12 Schering Ag Mikrobiologische Verfahren zur Herstellung von 7α-substituierten 11α-Hydroxysteroiden, daraus herstellbare 7α,17α-substituierte 11β-Halogensteroide, deren Herstellungsverfahren und Verwendung sowie pharmazeutische Präparate, die diese Verbindungen enthalten, sowie daraus herstellbare 7α-substituierte Estra-1,3,5(10)-triene
MXPA05001024A (es) * 2002-07-24 2005-05-16 Schering Ag Metodo microbiologico para la produccion de 11 alfa-hdiroxiesteroides sustituidos en la posicion 7 alfa.
JP2006502997A (ja) * 2002-07-25 2006-01-26 シエーリング アクチエンゲゼルシャフト アンドロゲン１１β‐ハロゲンステロイドおよびゲスタゲンを含有する組成物ならびにこの組成物に基づく男性用避妊薬
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
CN106188202B (zh) * 2014-10-08 2017-10-24 常州大学 副产3，17‑二醇物含量大幅降低的合成睾酮方法
TWI530504B (zh) * 2014-12-01 2016-04-21 臺灣永光化學工業股份有限公司 烷基酸睾酮化合物之合成方法
US20220411460A1 (en) * 2021-06-29 2022-12-29 Board Of Regents, The University Of Texas System Modified glucocorticoids

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB863661A (en) 1958-06-06 1961-03-22 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH380118A (de) * 1959-06-17 1964-07-31 Ciba Geigy Neue Halogenandrostenverbindungen und Verfahren zu deren Herstellung
FR1489519A (fr) 1965-08-16 1967-07-21 Glaxo Lab Ltd Procédé de préparation de nouveaux 19-nor-stéroïdes et produits obtenus
GB1159434A (en) * 1965-08-16 1969-07-23 Glaxo Lab Ltd 11beta&;-Fluoro-19-nor-Steroids
US3665021A (en) 1966-07-29 1972-05-23 Glaxo Lab Ltd 9alpha-unsubstituted-11beta-chloro-l9 nos-steroids
GB1260463A (en) 1968-01-29 1972-01-19 Glaxo Lab Ltd 11beta-BROMO-19-NOR-STEROIDS
DE2410443A1 (de) * 1974-03-01 1975-09-11 Schering Ag 11beta-fluor-androstene
DE2410442A1 (de) 1974-03-01 1975-09-11 Schering Ag Verfahren zur herstellung von 11-fluorandrostenen
DE3214690A1 (de) * 1982-04-16 1983-10-27 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-chlor-(delta)(pfeil hoch)1(pfeil hoch)(pfeil hoch)5(pfeil hoch)-steroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
US5342834A (en) * 1989-04-07 1994-08-30 The Population Council, Inc. Method for androgen supplementation
US6767902B2 (en) * 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
JP4749550B2 (ja) * 1999-03-08 2011-08-17 ナームローゼ・フエンノートチヤツプ・オルガノン アンドロゲンとしての１４β，１７α−ヒドロキシメチルアンドロスタン誘導体
US6756366B1 (en) * 1999-04-06 2004-06-29 Akzo Nobel N.V. Orally active androgens
DE19959696A1 (de) * 1999-12-08 2001-06-21 Jenapharm Gmbh Ungesättigte 14,15-Cyclopropano-Androstane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
PE20020848A1 (es) 2002-10-26
PL361730A1 (en) 2004-10-04
PT1353938E (pt) 2008-04-29
HUP0303020A2 (hu) 2003-12-29
PL207582B1 (pl) 2011-01-31
US7361645B2 (en) 2008-04-22
BR0206653A (pt) 2004-02-03
CZ20032006A3 (cs) 2004-01-14
NO20033321L (no) 2003-09-24
CA2434187A1 (en) 2002-08-01
EE05274B1 (et) 2010-02-15
TWI333494B (en) 2010-11-21
NO20033321D0 (no) 2003-07-23
CZ303553B6 (cs) 2012-12-05
DK1353938T3 (da) 2008-05-26
EA006674B1 (ru) 2006-02-24
KR100728088B1 (ko) 2007-06-14
EA200300756A1 (ru) 2004-02-26
RS50740B (sr) 2010-08-31
CY1110377T1 (el) 2015-04-29
EE200300346A (et) 2003-12-15
BG108023A (bg) 2004-02-27
DE60224982D1 (de) 2008-03-27
IL156807A (en) 2008-08-07
JP4339591B2 (ja) 2009-10-07
NZ527041A (en) 2005-02-25
EP1353938A1 (en) 2003-10-22
MXPA03006578A (es) 2003-09-22
SK287444B6 (sk) 2010-09-07
DE10104327A1 (de) 2002-07-25
DE60224982T2 (de) 2009-04-09
BG66133B1 (bg) 2011-06-30
NO325754B1 (no) 2008-07-14
WO2002059139A1 (en) 2002-08-01
CA2434187C (en) 2009-06-16
YU59403A (sh) 2006-08-17
KR20030081391A (ko) 2003-10-17
EP1353938B1 (en) 2008-02-13
US20050075322A1 (en) 2005-04-07
AU2002238516B2 (en) 2007-08-23
CN1234721C (zh) 2006-01-04
ATE386045T1 (de) 2008-03-15
IL156807A0 (en) 2004-02-08
SK9542003A3 (en) 2003-12-02
CN1487950A (zh) 2004-04-07
HRP20030661A2 (en) 2005-06-30
HRP20030661B1 (en) 2011-10-31
JP2004517153A (ja) 2004-06-10
UA75907C2 (en) 2006-06-15
ES2300431T3 (es) 2008-06-16
ZA200306537B (en) 2004-09-08
AR053299A1 (es) 2007-05-02
HK1064678A1 (en) 2005-02-04
HUP0303020A3 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
UY28342A1 (es) Nuevos compuestos
UY27604A1 (es) Compuestos químicos.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
ECSP066667A (es) Derivados de ciclohexano espirociclicos
UY27760A1 (es) Nuevos derivados de pirrolidinio.
UY27740A1 (es) Nuevos compuestos
UY27516A1 (es) Bencimidazoles
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
PT1263725E (pt) Novos compostos
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
HN2002000300A (es) Nuevos derivados de piperazina
AR029210A1 (es) DERIVADOS DE N-(5-SULFAMOIL-1,3-TIAZOL-2-IL) ACETAMIDA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTOS INTERMEDIARIOS, COMPOSICIoN FARMACÉUTICA, Y EL USO DE DICHOS DERIVADOS PARA LA PRODUCCIoN DE MEDICAMENTOS
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
UY28694A1 (es) Nuevos compuestos
AR022970A1 (es) Compuestos antagonistas de la lhrh con propiedades mejoradas de sulubilidad, procedimiento para prepararlos, las composiciones farmrceuticas que los contienen, su uso para la preparacinn de medicamentos, y procedimiento para preparar dichos medicamentos
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
UY27133A1 (es) 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
HN2001000235A (es) Derivados puentes de piperazina
PA8605101A1 (es) 4-(aminometil)-piperidin benzamidas como antagonista de 5ht4
SV2006002121A (es) Prodrogas de estradiol ref. p-sv-78.325/msu
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150429